Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: http://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
661 articles with Regeneron Pharmaceuticals, Inc.
-
Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.
-
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
9/15/2018
Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress
-
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
9/13/2018
The target action date for the FDA decision is May 13, 2019.
-
Regeneron plans to invest more than $800 million over seven years to expand its facilities in Rensselaer County, New York. This expansion is expected to create 1,500 new full-time jobs.
-
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
9/12/2018
Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
9/12/2018
* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
-
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
-
Although there is a general complaint about drug prices, which rocketed into the public domain during the 2016 U.S. presidential election, nothing particularly dramatic has been done about it.
-
Top 12 Biotech Companies Hiring Now
9/5/2018
Summer is coming to an end, but the job front is still sizzling. Check out the top companies who are looking for candidates like you right now! -
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
-
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...
8/27/2018
McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character. -
Regeneron Announces Upcoming September 2018 Investor Conference Presentation
8/24/2018
Regeneron Pharmaceuticals, Inc. will webcast its management presentation at the Morgan Stanley 16th Annual Global Healthcare Conference at 9:55 a.m. Eastern Time on Wednesday, September 12, 2018.
-
The U.S. Food and Drug Administration has posted new draft guidance that will guide drug and medical device manufacturers that aim to develop treatments for “the underlying pathophysiology and structural progression” of osteoarthritis (OA).
-
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look.
-
The U.S. Food and Drug Administration has done another about-face. Days after rejecting Regeneron’s attempt to secure a supplemental approval for Eylea, the FDA has now approved a new dosing label for the drug in wet age-related macular degeneration (wet AMD).
-
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
8/16/2018
Data include final primary efficacy results and an interim safety analysis
-
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
8/16/2018
Data include final primary efficacy results and an interim safety analysis
-
Regeneron and Teva’s Fasinumab Hits Primary and Secondary Endpoints in Late-Stage Sub Study
8/16/2018
Regeneron’s fasinumab hit the mark in a late-stage study assessing patients with chronic pain from osteoarthritis (OA) of the knee or hip. At 16 weeks patients experienced significantly less pain and also showed significantly improved functional ability from baseline. -
Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron's Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic
8/15/2018
According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis.